Active Enhancer Assessment by H3K27ac ChIP-seq Reveals Claudin-1 as a Biomarker for Radiation Resistance in Colorectal Cancer

• Egile Nagusiak: Zu-Xuan Chen MD (Egilea), He-Qing Huang MD (Egilea), Jia-Ying Wen MD (Egilea), Li-Sha Qin MD (Egilea), Yao-Dong Song MD (Egilea), Ye-Ying Fang MD (Egilea), Da-Tong Zeng MD (Egilea), Wei-Jian Huang MD (Egilea), Xin-Gan Qin MD (Egilea), Ting-Qing Gan MD (Egilea), Jie Luo MD (Egilea), Jian-Jun Li MD (Egilea)
• Formatua: Liburua
• Argitaratua: SAGE Publishing, 2021-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background Colorectal cancer (CRC) represents the third most common malignant tumor in the worldwide. Radiotherapy is the common therapeutic treatment for CRC, but radiation resistance is often encountered. ChIP-seq of Histone H3K27 acetylation (H3K27ac) has revealed enhancers that play an important...